REGN - REGENERON PHARMACEUTICALS, INC.
IEX Last Trade
1138.9
0 0%
Share volume: 379,448
Last Updated: Tue 24 Dec 2024 06:00:34 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$1,138.90
-428.59
0.60%
Fundamental analysis
57%
Profitability
68%
Dept financing
7%
Liquidity
72%
Performance
54%
Performance
5 Days
0.97%
1 Month
-4.59%
3 Months
-31.63%
6 Months
-32.78%
1 Year
-15.54%
2 Year
0.53%
Key data
Stock price
$1,138.90
DAY RANGE
$706.61 - $719.98
52 WEEK RANGE
$714.05 - $1,211.20
52 WEEK CHANGE
-$15.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Leonard S. Schleifer
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.
Recent news